HEK-Omics: The promise of omics to optimize HEK293 for recombinant adeno-associated virus (rAAV) gene therapy manufacturing
Gene therapy is poised to transition from niche to mainstream medicine, with recombinant adeno-associated virus (rAAV) as the vector of choice. However, this requires robust, scalable, industrialized production to meet demand and provide affordable patient access, which has thus far failed to materi...
Saved in:
Main Authors | , , , , , |
---|---|
Format | Journal Article |
Language | English |
Published |
23.08.2024
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Gene therapy is poised to transition from niche to mainstream medicine, with
recombinant adeno-associated virus (rAAV) as the vector of choice. However,
this requires robust, scalable, industrialized production to meet demand and
provide affordable patient access, which has thus far failed to materialize.
Closing the chasm between demand and supply requires innovation in
biomanufacturing to achieve the essential step change in rAAV product yield and
quality. Omics provides a rich source of mechanistic knowledge that can be
applied to HEK293, the prevailing cell line for rAAV production. In this
review, the findings from a growing number of disparate studies that apply
genomics, epigenomics, transcriptomics, proteomics, and metabolomics to HEK293
bioproduction are explored. Learnings from CHO-Omics, application of omics
approaches to improve CHO bioproduction, provide context for the potential of
"HEK-Omics" as a multiomics-informed approach providing actionable mechanistic
insights for improved transient and stable production of rAAV and other
recombinant products in HEK293. |
---|---|
DOI: | 10.48550/arxiv.2408.13374 |